Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 524-530
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.524
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.524
Hematologic parameters |
Hemoglobin |
White blood cell count |
Platelet count |
Hepatic parameters |
Alkalic phosphatase |
Gamma glutamyl transpeptidase |
Alanine aminotransferase |
Other parameters |
Creatinine |
C-reactive protein |
6-TGN (pmol/8 × 108 RBC) | 6-MMP (pmol/8 × 108 RBC) | Non-response | Adverse event (dose-dependent) | Recommendation |
<< 230 | << 5700 | Non-compliance | Not expected | Gain compliance |
< 230 | < 5700 | Non-compliance/under dosing | Not expected | Gain compliance/increase dose1 |
230-400 | < 5700 | Possible resistance to thiopurine therapy | Not expected | Increase dose1 or change therapy2 |
> 400 | < 5700 | Therapy resistance | Myelotoxicity | Change therapy2 |
< 230 | >> 5700 | Shunting | Myelotoxicity | Consider allopurinol3 or switch to TG4 |
< 230 | > 5700 | Shunting | Hepatotoxicity | Consider allopurinol, 5-ASA or switch to TG |
230-400 | > 5700 | Possible resistance to thiopurine therapy | Hepatotoxicity | Consider allopurinol3 or 5-ASA |
> 400 | > 5700 | Therapy resistance | Hepatotoxicity | Change therapy2 |
Myelotoxicity | Decrease dose5 |
- Citation: Meijer B, Mulder CJ, van Bodegraven AA, de Boer NKH. How I treat my inflammatory bowel disease-patients with thiopurines? World J Gastrointest Pharmacol Ther 2016; 7(4): 524-530
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/524.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.524